Rheumatoid Arthritis

Top Story

EMA to review marketing authorization application of biosimilar to candidate to Humira

May 24, 2017

The European Medicines Agency has accepted to review the marketing authorization application for the adalimumab biosimilar candidate FKB327 for the treatment of patients with rheumatoid arthritis, according to a company press release.

“We are delighted that [Europpean Medicines Agency] EMA has accepted this application,” Hideaki Nomura, president and chief executive officer of Fujifilm Kyowa Kirin Biologics, said in the release. “The acceptance of this filing brings us one step closer to meeting the demand for high-quality and affordable biopharmaceuticals.”

In the Journals

Factors of methotrexate-induced epidermal necrosis identified

May 23, 2017
Researchers identified early signs and risk factors of methotrexate-induced epidermal necrosis, and physicians should use caution when deciding when to prescribe…
FDA News

FDA approves Kevzara for rheumatoid arthritis

May 23, 2017
After a resubmission by Sanofi and Regeneron Pharmaceuticals Inc., the FDA has approved Kevzara for the treatment of patients with rheumatoid arthritis, according to a…
In the Journals

Smoking cessation 4 years prior to RA diagnosis associated with reduced mortality risk

May 19, 2017
Smoking cessation 4 years prior to a diagnosis of rheumatoid arthritis was linked to a reduced mortality risk, according to a recently published analysis. Jeffrey A
FDA News

EMA to review marketing authorization application of biosimilar to candidate to Humira

May 24, 2017
The European Medicines Agency has accepted to review the marketing authorization application for the adalimumab biosimilar candidate FKB327 for the…

In the Journals

Factors of methotrexate-induced epidermal necrosis identified

May 23, 2017
Researchers identified early signs and risk factors of methotrexate-induced epidermal necrosis, and physicians should use caution when deciding when…

FDA News

FDA approves Kevzara for rheumatoid arthritis

May 23, 2017
After a resubmission by Sanofi and Regeneron Pharmaceuticals Inc., the FDA has approved Kevzara for the treatment of patients with rheumatoid…

In the Journals

Smoking cessation 4 years prior to RA diagnosis associated with reduced mortality risk

May 19, 2017
Smoking cessation 4 years prior to a diagnosis of rheumatoid arthritis was linked to a reduced mortality risk, according to a recently published…

In the Journals

Children whose parents have RA had mortality rates similar to other children

May 18, 2017
Children of parents with rheumatoid arthritis had mortality rates similar to children with healthy parents, according to results of a nationwide…

In the Journals

Study: TNF inhibitors linked with ‘slightly increased’ risk for extra-articular RA

May 17, 2017
According to a recently published analysis of a community-based cohort, patients with rheumatoid arthritis treated with tumor necrosis factor…

Survey: Most patients with RA reported having pain daily or multiple times per week, despite treatment

May 15, 2017
According to a survey of 1,004 adults in the United States, 80% of patients with rheumatoid arthritis have reported that they have pain daily or…

In the Journals

Secukinumab seen as safe, effective in RA phase 3 trial, but not better than other second-line agents

May 12, 2017
Secukinumab was safe and effective for patients with rheumatoid arthritis, according to a recently published phase 3 trial; however, it did not…

Meeting NewsVideo

VIDEO: Interstitial lung disease on the rise in patients with RA, despite better control of RA

May 11, 2017
DESTIN, Fla. — At the Congress of Clinical Rheumatology Annual Meeting, Iris Zink, MSN, RN, president of the Rheumatology Nurses Society…

Meeting NewsVideo

VIDEO: How to treat difficult patients with RA

May 4, 2017
DESTIN, Fla. — At the Congress of Clinical Rheumatology Annual Meeting, John J. Cush, MD, from the Baylor Institute, spoke about how to treat…

More Headlines »
Advertisement
Advertisement